학술논문

Development of potent, orally bioavailable, and highly selective LRRK2 PROTAC degrader molecules as potential disease modifying therapeutics for Parkinson's disease
Document Type
Journal
Source
MOVEMENT DISORDERS; AUG 2023, 38 pS611-pS611, 1p. Supplement: 1
Subject
Language
English
ISSN
15318257